Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

DECEMBER 13, 2020

Senhwa was invited to present positive topline results from their global phase II trial, evaluating the combination of Silmitasertib plus Gemcitabine/Cisplatin compared to Gemcitabine/Cisplatin alone in the frontline treatment of patients with Cholangiocarcinoma. Session Date and Time: 1/17/2021, 2:30 PM-3:15 PM (PST).

Small Molecule 40

Small Molecule FDA Clinical Trials Treatment 40

The Pharma Data

JANUARY 25, 2021

26, 2021 13:00 UTC. –( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:16 UTC. Patent US10835501B2, which relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. Cannabinoids are a diverse class of small molecules that interact on the g-coupled receptor subtypes CB1 and CB2.

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — On January 8, 2021 , Shenzhen Chipscreen Biosciences Co., Comparing to Non-Small Cell Lung Cancer(NSCLC), it is still not clear about tumor driving gene in the development of SCLC, and thus it is lacking of targeted therapeutic treatment for this life threaten disease. SHENZHEN, China , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Therapies 92

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

MARCH 25, 2021

The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. The manuscript was published in the March 25, 2021 issue of NEJM. Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. About Abrocitinib.

Small Molecule 52

Small Molecule Therapies Treatment Disease 52

The Pharma Data

JANUARY 19, 2021

19, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. The offering is expected to close on January 22, 2021, subject to customary closing conditions. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

The Pharma Data

JANUARY 13, 2021

14, 2021 11:00 UTC. These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma,” said Michael Bozik, M.D., Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp. “We

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. Sumitovant is a global biopharmaceutical company with a pipeline similarly focused on uterine fibroids, advanced prostate cancer and endometriosis. .

Science 52

Science Small Molecule FDA Approval Therapies 52

LifeSciVC

AUGUST 5, 2024

But that initial quote isn’t from 2024, it is from an interview in 2021 with Mark Levin, CEO at Millennium (MIT Technology Review). The proteosome inhibitor, approved for treatment of multiple myeloma and mantle cell lymphoma, has been an important medicine for patients but it isn’t a product of the genomics revolution.

Molecular Biology 90

Molecular Biology Production Drug Development Small Molecule 90

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. FDA for the treatment of Cholangiocarcinoma. TAIPEI and SAN DIEGO , Jan. Chris Recknor at the Center for Advanced Research and Education (CARE) in Gainesville, Georgia.

Trials 40

Trials Treatment Small Molecule Hospitals 40

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — Q Biomed Inc. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. .

FDA 40

FDA Treatment Small Molecule Drugs 40

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. Cantor Fitzgerald & Co.

FDA Approval 52

FDA Approval Therapies Small Molecule FDA 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — AIkido Pharma Inc. Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy (“PRRT”) that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells.

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Cilia, Jackie; Hitchcock, Stephen (12 August 2021). Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 1c00820.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

JUNE 22, 2023

As the global leader in cell therapy, we appreciate the opportunity and responsibility of bringing this innovative treatment to as many eligible patients as possible who may benefit,” said Cindy Perettie, Executive Vice President and Global Head of Kite. “We Kite’s manufacturing facility in El Segundo, California, U.S. Source link: [link]

Therapies 40

Therapies Marketing Small Molecule Science 40

KIF1A

MAY 27, 2023

Lessard created and advanced KIF1A.ORG’s Therapeutic Acceleration Program, facilitating the creation of patient-derived cell lines, mouse models, and drug screening platforms that are the bedrock of our search for treatments. Read more to learn about the factors involved in incentivizing investment in rare disease treatments.

Science 94

Science Disease Small Molecule Research 94

The Pharma Data

JULY 18, 2021

Pfizer and BioNTech completed the rolling submission of the BLA in May 2021. On May 10, 2021, the FDA expanded the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to include individuals 12 through 15 years of age.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

DECEMBER 23, 2020

It’s almost 2021, and the whole world just wants to move on from COVID-19. The struggle is real, and BioSpace spoke with just a couple of companies endeavoring to make 2021 a happier new year for survivors now suffering from the life-altering after-effects of COVID-19. PureTech Health Plc., The trial is ongoing in the U.S.

Clinical Trials 52

Clinical Trials FDA Trials Small Molecule 52

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

JANUARY 19, 2021

20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. There is a great need for a disease-modifying treatment for the 5.3 CLARKSVILLE, Md.,

Disease 40

Disease Small Molecule Clinical Trials Therapies 40

The Pharma Data

JANUARY 3, 2021

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population. million, with the majority to be completed by the first quarter of 2021. SOUTH SAN FRANCISCO, Calif., million – $1.5

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

NOVEMBER 8, 2020

All Almirall’s production sites continue to operate at full capacity in order to be able to ensure the supply of medicines to all patients requiring treatment. Regulatory filings for Tirbanibulin have been completed and the product is under registration in the EU and the US, with a launch forecasted for the beginning of 2021.

Licensing 52

Licensing Licensing Marketing Production 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 24, 2021

25, 2021 12:00 UTC. Biomolecular condensate behavior is linked to numerous neurological diseases where there is a high medical need, including ALS, and I look forward to leading and innovating as part of the team at Faze as we work to transform treatment of these and other serious disorders.”. CAMBRIDGE, Mass.–(

Pharma Companies 52

Pharma Companies Small Molecule Science Disease 52

The Pharma Data

DECEMBER 15, 2020

Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma. The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

KIF1A

MAY 31, 2024

From hosting a conference to scientific projects and collaborations to the dedicated efforts of our team, this review encapsulates the relentless pursuit to accelerate treatments and a cure for all KAND warriors. The Chung Lab spearheads a robust KAND program to better understand the disorder and discover treatments.

Treatment 52

Treatment Small Molecule International Research 52

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Clinical Development Small Molecule Packaging 52

The Pharma Data

JANUARY 4, 2021

5, 2021 06:30 UTC. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021. Further details on the trial design will be communicated in H2 2021.

Clinical Trials 40

Clinical Trials Small Molecule Therapies Treatment 40

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — IDEAYA Biosciences, Inc. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.

FDA 52

FDA Clinical Trials Small Molecule Therapies 52

The Pharma Data

DECEMBER 15, 2020

a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief Commercial Officer (CCO). . Joins AB2 Bio from Novartis and has extensive commercial and strategic experience.

Small Molecule 40

Small Molecule Disease Therapies Treatment 40

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration (FDA) Breakthrough Therapy and Fast Track Designations, is now in pivotal testing, and CTP-692 for schizophrenia is currently on track for topline data readout in the first quarter of 2021,” said Roger Tung, Ph.D., CTP-543: An Investigational Treatment for Moderate to Severe Alopecia Areata.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52